Andrea Passalacqua was appointed General Manager, Europe, in March 2021.
Andrea has extensive commercial experience within the biotech and pharmaceutical industry and significant therapeutic area expertise in the fields of hematology, oncology, inflammation and immunology.
Before joining Oncopeptides, Andrea was General Manager in Italy for Bluebird bio, where he led the preparation for a gene therapy launch in Italy. Previously, he served as Business Unit Director for Amgen Switzerland in the Inflammation and Immunology Unit. Earlier, he was Business Unit Director for Celgene Switzerland where he was responsible for the hematology, oncology and inflammation and immunology units.
During his 11-years tenure at Celgene he also held several leading international roles in different geographies including: Business Unit Director Spain, Executive Director Pricing and Market Access Europe, Senior Director Global Marketing Oncology, and Director European Oncology Franchise. Prior to joining the biotech industry, Andrea was working as a consultant at McKinsey & Company.
Andrea holds an MBA from IESE Business School (University of Navarra, Spain) and a degree in Telecom Engineering from the University La Sapienza in Rome, Italy.
Holdings in Oncopeptides: 50,000 options**.
Other Current positions: -